Pharvaris (NASDAQ:PHVS) Stock Price Down 6.6%

Pharvaris (NASDAQ:PHVSGet Free Report) dropped 6.6% during mid-day trading on Monday . The stock traded as low as $17.55 and last traded at $17.71. Approximately 55,871 shares were traded during trading, a decline of 39% from the average daily volume of 91,132 shares. The stock had previously closed at $18.96.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. Wedbush decreased their price objective on shares of Pharvaris from $35.00 to $31.00 and set an “outperform” rating for the company in a research report on Thursday, May 9th. JMP Securities lifted their price target on Pharvaris from $49.00 to $50.00 and gave the stock a “market outperform” rating in a report on Thursday, April 11th. Finally, Morgan Stanley restated an “overweight” rating and issued a $34.00 price objective on shares of Pharvaris in a research note on Monday, April 22nd.

Get Our Latest Research Report on Pharvaris

Pharvaris Price Performance

The stock has a 50-day simple moving average of $21.22 and a 200-day simple moving average of $23.94.

Pharvaris (NASDAQ:PHVSGet Free Report) last announced its quarterly earnings results on Wednesday, May 8th. The company reported ($0.56) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.56). On average, equities research analysts forecast that Pharvaris will post -2.39 EPS for the current year.

Hedge Funds Weigh In On Pharvaris

Hedge funds have recently modified their holdings of the business. Walleye Capital LLC increased its position in Pharvaris by 15.2% during the 3rd quarter. Walleye Capital LLC now owns 81,017 shares of the company’s stock valued at $1,691,000 after purchasing an additional 10,691 shares during the period. Hudson Bay Capital Management LP acquired a new stake in shares of Pharvaris during the third quarter worth $812,000. Blackstone Inc. bought a new position in Pharvaris during the fourth quarter worth $2,805,000. Vivo Capital LLC acquired a new position in Pharvaris in the fourth quarter valued at $7,994,000. Finally, venBio Partners LLC boosted its position in Pharvaris by 15.4% during the fourth quarter. venBio Partners LLC now owns 4,919,504 shares of the company’s stock valued at $137,992,000 after acquiring an additional 654,832 shares during the last quarter.

About Pharvaris

(Get Free Report)

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.

Further Reading

Receive News & Ratings for Pharvaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharvaris and related companies with MarketBeat.com's FREE daily email newsletter.